Drug Trial Radar · NCT07227597
A Clinical Study of Gocatamig (MK-6070) and Infinatamab Deruxtecan (MK-2400) in People With Small Cell Lung Cancer (MK-6070-003)
Last checked: Nov 20, 2026Latest source record: Nov 9, 2026 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Recruiting
Enrollment
170
Planned (sponsor's estimate)
Start
Jan 29, 2026
Primary completion
Nov 29, 2030
Study completion Dec 30, 2030
Sponsor
- Lead sponsor
- Merck Sharp & Dohme LLCMerck & Co. (MRK)
- Sponsor type
- Industry
- Collaborators
- Daiichi Sankyo
- First posted
- Nov 12, 2025
Design
- Study type
- Interventional
- Phase
- Phase 1 / Phase 2
- Allocation
- Randomized
- Model
- Parallel
- Masking
- None
- Primary purpose
- Treatment
- FDA-regulated drug
- Yes
- Who can join
- All sexes, from 18 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
Researchers are looking for new ways to treat extensive-stage small cell lung cancer (ES-SCLC). ES-SCLC is a type of lung cancer that has spread throughout the lung, to the other lung, or to other parts of the body. A standard (usual) treatment for ES-SCLC uses both chemotherapy and immunotherapy. * Chemotherapy is a treatment that works to destroy cancer cells or stop them from growing. * Immunotherapy is a treatment that helps the immune system fight cancer. Gocatamig and I-DXd (short for ifinatamab deruxtecan) are study medicines. Researchers want to know if giving gocatamig and I-DXd together can treat ES-SCLC. Researchers will also look at giving the study medicines with standard treatment. Gocatamig is a T-cell engager therapy. I-DXd is an antibody drug conjugate. * T-cell engager therapy is a certain type of immunotherapy that uses T-cells to find and destroy cancer cells. * A T-cell is a type of white blood cell, which are cells that help the body fight infection. * An antibody drug conjugate (ADC) is a treatment that attaches to a protein on cancer cells and delivers treatment to destroy those cells. The goals of this study are to learn: * About the safety of combining gocatamig and I-DXd and if people tolerate them together * If people who receive gocatamig and I-DXd have ES-SCLC respond, which means the cancer gets smaller or goes away
Conditions
- Small Cell Lung Cancer Extensive Stage
Interventions
GocatamigDrug
Intravenous (IV) administration
I-DXdDrug
IV administration
AtezolizumabDrug
IV administration
CarboplatinDrug
IV administration
EtoposideDrug
IV administration
Rescue MedicationsDrug
Participants will receive rescue medications at the investigator's discretion. Recommended rescue medications include tocilizumab for treatment of cytokine release syndrome (CRS); dexamethasone, acetaminophen, and diphenhydramine for CRS/infusion-related reaction (IRR) prophylaxis; and 5-hydroxytryptamine 3 (5-HT3) receptor antagonist, neurokinin 1 (NK-1) receptor antagonist, and corticosteroid for prevention of nausea and vomiting.
Primary outcomes
What the sponsor says the trial is designed to measure.
- Number of Participants Who Experience an Adverse Event (AE)Time frame: Up to approximately 58 months
- Number of Participants Who Experience One or More Dose-Limiting Toxicities (DLTs)Time frame: Up to approximately 21 days
- Number of Participants Who Discontinue Study Intervention Due to an AETime frame: Up to approximately 58 months
- Objective Response Rate (ORR)Time frame: Up to approximately 58 months
Locations
58 sites in 13 countries. Site status is shown where the registry gives one.
Providence Medical Foundation ( Site 0124)
Santa Rosa, California · Recruiting
University of Colorado, Anschutz Cancer Pavilion ( Site 0125)
Aurora, Colorado · Recruiting
Orlando Health Cancer Institute ( Site 0108)
Orlando, Florida · Recruiting
Saint Elizabeth Medical Center Edgewood ( Site 0112)
Edgewood, Kentucky · Recruiting
Washington University School of Medicine ( Site 0134)
St Louis, Missouri · Recruiting
John Theurer Cancer Center at Hackensack University Medical Center ( Site 0101)
Hackensack, New Jersey · Recruiting
Providence Cancer Institute, Franz Clinic - Eastside ( Site 0107)
Portland, Oregon · Recruiting
Avera Cancer Institute- Research ( Site 0104)
Sioux Falls, South Dakota · Recruiting
The University of Tennessee Medical Center ( Site 0120)
Knoxville, Tennessee · Recruiting
Lt. Col. Luke Weathers, Jr. VA Medical Center ( Site 0133)
Memphis, Tennessee · Recruiting
SCRI Oncology Partners ( Site 7000)
Nashville, Tennessee · Recruiting
Houston Methodist Hospital - Houston Methodist Neal Cancer Center ( Site 0113)
Houston, Texas · Recruiting
University of Virginia Health System ( Site 0122)
Charlottesville, Virginia · Recruiting
CEMIC ( Site 1903)
Caba., Buenos Aires, Argentina · Recruiting
Hospital Austral ( Site 1901)
Pilar, Buenos Aires, Argentina · Recruiting
Sanatorio Parque ( Site 1900)
Rosario, Santa Fe Province, Argentina · Recruiting
Fundación Arturo López Pérez ( Site 0200)
Santiago, Region M. de Santiago, Chile · Recruiting
Pontificia Universidad Catolica de Chile ( Site 0202)
Santiago, Region M. de Santiago, Chile · Recruiting
Bradfordhill ( Site 0201)
Santiago, Region M. de Santiago, Chile · Recruiting
Beijing Cancer Hospital ( Site 1604)
Beijing, Beijing Municipality, China · Recruiting
Fujian Provincial Cancer Hospital ( Site 1607)
Fuzhou, Fujian, China · Recruiting
Southern Medical University Nanfang Hospital ( Site 1608)
Guangzhou, Guangdong, China · Recruiting
Jiangmen Central Hospital ( Site 1611)
Jiangmen, Guangdong, China · Recruiting
Harbin Medical University Cancer Hospital ( Site 1606)
Harbin, Heilongjiang, China · Recruiting
The First Affiliated Hospital of Nanchang University ( Site 1610)
Nanchang, Jiangxi, China · Recruiting
Shanghai East Hospital ( Site 1600)
Shanghai, Shanghai Municipality, China · Recruiting
Sichuan Cancer hospital. ( Site 1609)
Chengdu, Sichuan, China · Recruiting
The first Affiliated Hospital, Zhejiang University School of Medicine ( Site 1602)
Hangzhou, Zhejiang, China · Recruiting
Taizhou Hospital of Zhejiang Province ( Site 1601)
Taizhou, Zhejiang, China · Recruiting
Universitaetsklinikum Tuebingen-Department of Internal Medicine VIII - Medical Oncology, ECTU, Pne ( Site 0401)
Tübingen, Baden-Wurttemberg, Germany · Recruiting
Universitaetsklinikum Jena ( Site 0403)
Jena, Thuringia, Germany · Recruiting
European Interbalkan Medical Center ( Site 0500)
Thessaloniki, Greece · Recruiting
European Interbalkan Medical Center ( Site 0505)
Thessaloniki, Greece · Recruiting
Errikos Dunant Hospital Center ( Site 0501)
Athens, Attica, Greece · Recruiting
THORACIC GENERAL HOSPITAL OF ATHENS "I SOTIRIA" ( Site 0502)
Athens, Attica, Greece · Recruiting
Athens Medical Center ( Site 0504)
Athens, Attica, Greece · Recruiting
University General Hospital of Heraklion ( Site 0503)
Heraklion, Irakleio, Greece · Recruiting
Rambam Health Care Campus ( Site 0602)
Haifa, Israel · Recruiting
Sheba Medical Center ( Site 0601)
Ramat Gan, Israel · Recruiting
Fondazione IRCCS Istituto Nazionale dei Tumori ( Site 0701)
Milan, Italy · Recruiting
Showing 40 of 58 sites, US sites first. The full list is on the registry record.
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.